Fostering orphan receptors: an indispensable role for integrative, in vivo haemodynamic studies

被引:8
作者
Bennett, T [1 ]
Gardiner, SM [1 ]
机构
[1] Queens Med Ctr, Ctr Integrated Syst Biol & Med, Sch Biomed Sci, Sch Med, Nottingham NG7 2UH, England
关键词
D O I
10.1016/S1471-4892(03)00004-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The assessment of cardiovascular effects of well-recognised ligands for their known receptors can produce misleading results if measurements are restricted to blood pressure and heart rate in anaesthetised animals. Therefore, we propose that the most reliable delineation of any role for a particular ligand-receptor system in cardiovascular regulation can only be achieved by determination of the detailed haemodynamic effects of manipulating the system in vivo, in the absence of anaesthesia. This approach is powerful because, firstly, differences between in vitro and in vivo effects, possibly attributable to disparities between receptor genotype and receptor phenotype, are highlighted; and secondly, regional heterogeneity of cardiovascular effects, possibly in the absence of changes in systemic arterial blood pressure, can be detected.
引用
收藏
页码:140 / 145
页数:6
相关论文
共 45 条
[1]   Evidence that the angiotensin IV (AT4) receptor is the enzyme insulin-regulated aminopeptidase [J].
Albiston, AL ;
McDowall, SG ;
Matsacos, D ;
Sim, P ;
Clune, E ;
Mustafa, T ;
Lee, J ;
Mendelsohn, FAO ;
Simpson, RJ ;
Connolly, LM ;
Chai, SY .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (52) :48623-48626
[2]   Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 [J].
Ames, RS ;
Sarau, HM ;
Chambers, JK ;
Willette, RN ;
Alyar, NV ;
Romanic, AM ;
Louden, CS ;
Foley, JJ ;
Sauermelch, CF ;
Coatney, RW ;
Ao, ZH ;
Disa, J ;
Holmes, SD ;
Stadel, JM ;
Martin, JD ;
Liu, WS ;
Glover, GI ;
Wilson, S ;
McNulty, DE ;
Ellis, CE ;
Elshourbagy, NA ;
Shabon, U ;
Trill, JJ ;
Hay, DWP ;
Ohlstein, EH ;
Bergsma, DJ ;
Douglas, SA .
NATURE, 1999, 401 (6750) :282-286
[3]   Mechanisms underlying tissue selectivity of anandamide and other vanilloid receptor agonists [J].
Andersson, DA ;
Adner, M ;
Högestätt, ED ;
Zygmunt, PM .
MOLECULAR PHARMACOLOGY, 2002, 62 (03) :705-713
[4]  
Bennett T., 2002, British Journal of Pharmacology, V135, p38P
[5]  
Bennett T., 2002, British Journal of Pharmacology, V135, p200P
[6]   The mechanisms of action of PPARs [J].
Berger, J ;
Moller, DE .
ANNUAL REVIEW OF MEDICINE, 2002, 53 :409-435
[7]   Urotensin II evokes potent vasoconstriction in humans in vivo [J].
Böhm, F ;
Pernow, J .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 135 (01) :25-27
[8]   FMRFamide-related neuropeptides are agonists of the orphan G-protein-coupled receptor GPR54 [J].
Clements, MK ;
McDonald, TP ;
Wang, RP ;
Xie, GC ;
O'Dowd, BF ;
George, SR ;
Austin, CP ;
Liu, QY .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 284 (05) :1189-1193
[10]   Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey [J].
Elshourbagy, NA ;
Douglas, SA ;
Shabon, U ;
Harrison, S ;
Duddy, G ;
Sechler, JL ;
Ao, ZH ;
Maleeff, BE ;
Naselsky, D ;
Disa, J ;
Aiyar, NV .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 136 (01) :9-22